- Methylene blue trihydrate
- Drug Entry
- Methylene blue
Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated.
Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease.
- Accession Number
- C.I. basic blue 9 trihydrate / Methylene blue / Methylthioninium chloride trihydrate
- CAS Number
- Average: 373.9
- Chemical Formula
- InChI Key
- IUPAC Name
- 7-(dimethylamino)-N,N-dimethyl-3H-phenothiazin-3-iminium trihydrate chloride
- Predicted Properties
Property Value Source Water Solubility 0.0114 mg/mL ALOGPS logP -1.1 ALOGPS logP -0.62 ChemAxon logS -4.4 ALOGPS pKa (Strongest Basic) 3.14 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 18.61 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 103.88 m3·mol-1 ChemAxon Polarizability 33.12 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon